On September 25, 2026, Lantern Pharma Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of lis...
This Securities Purchase Agreement (this “Agreement”) is dated as of September 28, 2026, between Lantern Pharma Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including it...
On September 23, 2026, Lantern Pharma Inc. (the “Company”) hosted a live webinar to discuss the Open-Medicine AI multi-agentic AI platform for drug development.
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
